Used in the treatment of moderate to severe atopic dermatitis, particularly in patients unresponsive to topical therapies. It targets the IL-4 receptor alpha subunit to inhibit signaling of interleukin-4 and interleukin-13, key drivers of type 2 inflammation. Also approved for use in asthma, especially eosinophilic or oral steroid-dependent types, and chronic rhinosinusitis with nasal polyps. Helps reduce flare-ups, improve lung function, decrease polyp size, and enhance quality of life.

Administered subcutaneously at regular intervals as prescribed by a physician, it demonstrates long-term benefits with continued use.

Employed in research settings as a reference antibody for assay development and bioanalytical testing.